Identification of telomere-related lncRNAs and immunological analysis in ovarian cancer

Weina Xu; Shuliu Sang; Jun Wang; Shanshan Guo; Xiao Zhang; Hailun Zhou; Yijia Chen

doi:10.3389/fimmu.2024.1452946

Frontiers in Immunology (Sep 2024)

Identification of telomere-related lncRNAs and immunological analysis in ovarian cancer

Weina Xu,
Shuliu Sang,
Jun Wang,
Shanshan Guo,
Xiao Zhang,
Hailun Zhou,
Yijia Chen

Affiliations

Weina Xu: Department of TCM, Zhoujiadu Community Health Service of Shanghai Pudong New Area, Shanghai, China
Shuliu Sang: Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Jun Wang: Department of TCM, Zhoujiadu Community Health Service of Shanghai Pudong New Area, Shanghai, China
Shanshan Guo: Department of Gynecology, Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
Xiao Zhang: Department of Gynecology, Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
Hailun Zhou: Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Yijia Chen: Department of Gynecology, Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

DOI: https://doi.org/10.3389/fimmu.2024.1452946
Journal volume & issue: Vol. 15

Abstract

Read online

BackgroundOvarian cancer (OC) is a global malignancy characterized by metastatic invasiveness and recurrence. Long non-coding RNAs (lncRNAs) and Telomeres are closely connected with several cancers, but their potential as practical prognostic markers in OC is less well-defined.MethodsRelevant mRNA and clinical data for OC were sourced from The Cancer Genome Atlas (TCGA) database. The telomere-related lncRNAs (TRLs) prognostic model was established by univariate/LASSO/multivariate regression analyses. The effectiveness of the TRLs model was evaluated and measured via the nomogram. Additionally, immune infiltration, tumor mutational load (TMB), and drug sensitivity were evaluated. We validated the expression levels of prognostic genes. Subsequently, PTPRD-AS1 knockdown was utilized to perform the CCK8 assay, colony formation assay, transwell assay, and wound healing assay of CAOV3 cells.ResultsA six-TRLs prognostic model (PTPRD-AS1, SPAG5-AS1, CHRM3-AS2, AC074286.1, FAM27E3, and AC018647.3) was established, which can effectively predict patient survival rates and was successfully validated using external datasets. According to the nomogram, the model could effectively predict prognosis. Furthermore, we detected the levels of regulatory T cells and M2 macrophages were comparatively higher in the high-risk TRLs group, but the levels of activated CD8 T cells and monocytes were the opposite. Finally, the low-risk group was more sensitive to anti-cancer drugs. The mRNA levels of PTPRD-AS1, SPAG5-AS1, FAM27E3, and AC018647.3 were significantly over-expressed in OC cell lines (SKOV3, A2780, CAOV3) in comparison to normal IOSE-80 cells. AC074286.1 were over-expressed in A2780 and CAOV3 cells and CHRM3-AS2 only in A2780 cells. PTPRD-AS1 knockdown decreased the proliferation, cloning, and migration of CAOV3 cells.ConclusionOur study identified potential biomarkers for the six-TRLs model related to the prognosis of OC.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords